OurPharma LLC, Fayetteville, AR

Is OurPharma LLC an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names OurPharma LLC in Fayetteville, AR, first registered Mar 15, 2019 and most recently registered Nov 26, 2025. FDA lists its last inspection as Aug 12, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Fayetteville, AR
Initial registration
Mar 15, 2019
Most recent registration
Nov 26, 2025
Last inspection
Aug 12, 2026
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Open
Intends to compound sterile drugs from bulk substances
Yes
Earlier inspections
FDA notes that an earlier inspection led to a Form 483, warning letter or other action

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as OurPharma LLC, Fayetteville, AR, a 503B facility, with 5 listed actions, including 3 Form 483s (2021 to 2026).

Document
Aug 12, 2026Form 483483 Issued 08/12/2026fda.gov
Jun 23, 2025FMD-145 letterFMD-145 Letter Issued 06/23/2025Not linked by FDA
Sep 27, 2024Form 483483 Issued 09/27/2024FDA copy (archived)
Mar 14, 2022FMD-145 letterFMD-145 Letter Issued 03/14/2022Not linked by FDA
Sep 30, 2021Form 483483 Issued 09/30/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists OurPharma LLC, Fayetteville, AR (FEI number 3014064135), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 27, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30140641351250182
Sep 30, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30140641351153244

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 10 numbered observations in all, across 3 inspections ending Sep 30, 2021 to Aug 12, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 3, 2026 to Aug 12, 2026: 3 observations

Firm on the cover
OurPharma LLC, 2512 S City Lake Rd, Fayetteville, AR 72701-5013
FEI number
3014064135
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of diu g products.

Specifically,

• <Redacted B4> Sterilization Performed in an ISO 8 Classified Room Batch records collected during the inspection confirm that <Redacted B4> sterilization was performed in Compounding Room <Redacted B4> which is classified as ISO 8. Specifically: Batch production records for two lots of Fentanyl Citrate/Bupivacaine HCl combination products, Lot 1019-01-2608-01 (Fentanyl Citrate 2mcg[base]/mL + Bupivacaine HCl 0.125% in <Redacted B4> added to l00mL 0.9% NaCl Bag; Master Production Batch Record No. GMP-PDT Methods-0218, Revision 01, Effective Date: July 9, 2026) and Lot 1081 -01-2608-01 (Fentanyl Citrate 2mcg[base ]/mL + Bupivacaine HCl 0.1 % in SWFI added to 100mL 0.9% NaCl Bag; Master Production Batch Record No. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.

Specifically,

Annual product review (APR) records for six drug product families -Fentanyl Citrate, Fentanyl Citrate + Bupivacaine HCl, Fentanyl Citrate + Ropivacaine HCl, Hydromorphone HCl, Morphine HCl, and Ropivacaine HCl, covering review period 2024-2025 -contain multiple numerical inconsistencies, cross-product data errors, and documentation inaccuracies. When presented with these findings during the inspection, firm management confirmed that the errors were mistakes and that connected records had not been issued prior to the inspection.

cross-product data en ors, and documentation inaccuracies. When presented with these findings during the inspection, fum management confnmed that the enors were mistakes and that con ected records had not been issued prior to the inspection.

DATA INTEGRITY & STATISTICAL ERRORS

APR Document

Error Category

Finding Detail

Pentanyl Citrate + Bupivacaine HCl APR

Irreconcilable Batch Disposition Percentages ...

Read the full 483 (PDF on fda.gov)

Observation 3

Dmg product production and control records, are not reviewed by the quality control unit to dete1mine compliance with all established, approved written procedures before a batch is released or distributed.

Specifically,

Your Out of Specification (OOS) procedure, GMP-SOP-0047 (Out of Specification (OOS) SOP), does not establish defined timeframes for the completion of OOS investigations, including maximum allowable durations for Phase I laboratory investigations or Phase II full -scale investigations, nor does it define criteria or approval requirements governing the use of supplemental justifications to extend investigations beyond an initial target. During the inspection, firm management indicated that investigations typically take approximately <Redacted B4> days but have extended to approximately <Redacted B4> days, at which point a supplemental justification is added to the investigation record. Review of 13 OOS investigation records revealed that 9 required extension justifications, with open durations ranging from 35 to 205 days. ...

Read the full 483 (PDF on fda.gov)

Inspection Sep 16, 2024 to Sep 27, 2024: 5 observations

Firm on the cover
OurPharma LLC, 2512 S City Lake Rd, Fayetteville, AR 72701-5013
FEI number
3014064135
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

a) In November 2023, your firm changed manufacturers of the Fentanyl Citrate, USP and in February 2024 your firm changed manufacturers of the Morphine Sulfate, USP. These active pharmaceutical ingredients (API) are used to make various drug products such as Fentanyl Citrate 1 00mcg (2mcg/ml) + Bupivacaine HCI 0.125% in 0.9% NaCl -50ml in 60ml syringe, Fentanyl Citrate 500mcg (2mcg/ml) + Bupivacaine HCI 0.125% in SWFI -added to 250ml 0.9% NaCl, Fentanyl Citrate 1mg in SWFI -added to 100ml 0.9% NaCl bag = 1 0mcg/ml, Fentanyl Citrate 200mcg (2mcg/ml) + Bupivacaine HCI 0.125% in 0.9% NaCl -100ml cassette, Morphine Sulfate 1mg/ml (API) in 0.9% NaCl -30ml in 30ml PCA vial, and Morphine Sulfate 1mg/ml (API) in 0.9% NaCl -30ml in 35 ml monoject plungerless syringe. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 2

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, positive pressure is not always maintained between rooms of different classifications, when doors are opened e.g. between the ISO 7 Ante Rooms where gowning occurs to enter each suite and the ISO 8 corridor and the ISO 8 corridor and the controlled but not classified Changing Room. Your firm has not performed a risk assessment and/or smoke studies to demonstrate that lower quality air is not entering areas of higher quality air.

Observation 3

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(1 0)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

AM ENDMENT 1

Specifically, the following information is not found on your drug product labels:

a) The name, address, and phone number of the outsourcing facility.

b) The statement "Not for resale", and, if the drug is dispensed or distributed other than pursuant to a prescription for an individual identified patient, the statement "Office Use Only".

Examples of your drug product labels that do not contain this information:

• Ketamine HCI 25 mg/1 ml Injection in a 3 ml Syringe

Observation 4

The container of your outsourcing facility's drug products does not include information required by section 503B(a)(10)(8) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically, your containers do not include the following information:

a) Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088.

AMENDMENT 1

b) Directions for use, including, as appropriate, dosage and administration.

Examples of your container labels that do not contain this information:

• Fentanyl Citrate 10 mcg/ml Injection in a 100 ml bag

• Fentanyl Citrate 100 mcg/50 ml + Bupivacaine HCI 0.125% in 60 ml Syringe

• Hydromorphone HCI 30 mg/30 ml Injection in a 30 ml Syringe

• Ropivacaine HCI 0.2% Injection in a 500 ml bag

Observation 5

Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically, the following products were compounded and not identified on your report dated December 2023:

• Fentanyl Citrate 2mcg/ml + Bupivacaine HCI 0.125% (PF) added to NS 250mlBag

Inspection Sep 20, 2021 to Sep 30, 2021: 2 observations

Firm on the cover
OurPharma LLC, 2512 s City Lake Rd, Fayetteville, AR 72701-5013
FEI number
3014064135
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm has no documented justification for the orientation of the non-viable particle monitoring probes located in the ISO 5 biological safety cabinets (BSC). The placement of the isokinetic probe is not fixed and is bumped and moved during cleaning of the BSCs. Your firm cannot demonstrate that the orientation and placement of the probes provides a meaningful sample.

In addition your firm has not qualified under actual conditions of use the non-viable particulate probes and the active air samplers within the ISO 5 BSCs. The system was initially qualified <Redacted B4> and the BSCs were not installed until sometime in January/Febrnmy 2019.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.

Specifically, your firm did not include the material used for the arm rests on the ISO 5 Biological Safety Cabinets (BSC) in your disinfectant efficacy study. Your firm has no documentation to show that the disinfectants used are effective on this material.

In addition, your firm has not evaluated the suitability of the material used for the arm rests for use in an IS05/ISO 7 cleanroom environment or for use in sterile production.

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (OurPharma LLC). That is not a finding beyond this index’s search.

The OurPharma LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 3 products naming semaglutide under the labeler name “OurPharma LLC”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (3). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
73013-9000SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
73013-9001SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs
73013-9002SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.